Potassium citrate mixture
Available from a pharmacy with pharmacist advice
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Potassium citrate + Citric acid
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
MHRA licensed products
View all licensed products for Potassium citrate + Citric acid on the MHRA register
Potassium citrate mixture
Potassium citrate mixture
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
4 gram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 3 · Randomised trials: 6 · 1943–2026
Showing the 50 most relevant studies, sorted by most relevant.
Baker B, Herforth C, Low J, et al.
2026
- Malus
- Acetic Acid
- Urolithiasis
PurposeTo evaluate the potential stone-preventative effects of apple cider vinegar (ACV) supplementation on 24-h urinary citrate, pH, and volume.MethodsWe performed a randomized crossover trial testing ACV, coconut water, lemon water, and orange soda. Participants were non-stone formers randomized to two of the four beverages. Participants consumed one assigned beverage daily for one week, underwent a two-week washout period, and then consumed the second assigned beverage. Three 24-h urine collections were planned: one baseline collection prior to beverage consumption, one following completion of the first treatment week, and one following completion of the second week.ResultsTwenty participants were enrolled. Eight were female. Six consumed ACV, six coconut water, eight lemon water, and six diet orange soda. ACV did not significantly change 24-h urinary parameters. Coconut water (+ 273.8 mg/24 h, 95% CI 67.9-480 mg/24 h) and lemon water (+ 167.7 mg/24 h, 95% CI 16-319 mg/24 h) were associated with increased urinary citrate. Effects on urine pH and volume were not significant in any treatment arms.ConclusionACV did not significantly change 24-h urine parameters. Coconut water and lemon water increased urinary citrate. Further study is necessary to validate these findings in a larger cohort. Registered with ClinicalTrials.gov (NCT04073719, 8/28/2019).
Abstract licence: CC BY
Li P, Yang X, Lang Y, et al.
2025
- Calcium Oxalate
- Urolithiasis
- Kidney Calculi
Ricapito A, Schiavone N, Finati M, et al.
2025
- Postoperative Complications
- Citrates
- Citric Acid
Guo JN, Patel A, Tsai KP, et al.
2026
BackgroundPotassium citrate (KCit) is commonly prescribed to patients with recurrent nephrolithiasis; however, medication compliance is poor due to gastrointestinal side-effects. Crystal Light® (CL) sugar-free lemonade is a low-calorie beverage alternative that has been shown to increase urinary citrate and pH levels. In this study, we aimed to compare the effects of KCit, CL, and CL + KCit on 24-hour urine collections in hypocitraturic stone formers.MethodsWe performed a randomized crossover trial of 8 patients with isolated hypocitraturia on 24-hour urine collections. Patients completed three 1-week trials of KCit (15 mEq daily), CL (1 L daily), and combination CL and KCit (500 mL + 10 mEq daily) followed by immediate 24-hour urine collections after each weekly treatment. There was a washout period of 1 week in between each regimen. Statistical analysis was conducted with Kruskal-Wallis rank sum tests and linear mixed-effects models.ResultsThe CL regimen led to the greatest increases in urinary volume (CL: 0.53 vs. KCit: -0.08 vs. CL + KCit: 0.21 L, P=0.5) and combination regimen had the greatest increase in urinary citrate (CL: 172 vs. KCit: 68 vs. CL + KCit: 173, P=0.8) from baseline. However, these differences did not reach statistical significance. The CL regimen led to a mean increase in pH of 0.42 compared to 0.25 with CL + KCit and 0.18 with KCit (P=0.6). There were similar increases in supersaturation (SS) of calcium phosphate in all regimens (CL: 0.2 vs. KCit: 0.08 vs. CL + KCit: 0.22, P>0.9). The SS of calcium oxalate (CaOx) decreased by 0.15 in the CL regimen and 1.39 in the KCit regimen but showed slight increases in the combination regimen (0.47, P>0.9). On pairwise comparison after linear mixed effects models were performed, CL resulted in a significantly greater reduction in SS uric acid compared with KCit (mean difference =-0.49, P=0.002).ConclusionsIn this limited study in active stone formers with hypocitraturia, consumption of a low-calorie sugar-free citrate-containing lemonade beverage was well tolerated with no reported adverse effects. Multi-institutional studies are needed to determine clinical significance.Trial registrationClinicalTrials.gov NCT05389995.
Abstract licence: CC BY-NC-ND
Veraza JA, Veraza SA, Almeida MZ
2026
D.A. Bossio, K.M. Scow
Microbial Ecology, 1998
W.F. Wonderlin, J.S. Strobl
Journal of Membrane Biology, 1996
Eric Jauniaux, Adrian Watson, Graham Burton
American Journal of Obstetrics and Gynecology, 2001
Hong Xie, J.J. Pasternak, Bernard R. Glick
Current Microbiology, 1996
Randy M. Becker, Guoyao Wu, Joseph A. Galanko, et al.
The Journal of Pediatrics, 2000
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.